SARS (Severe Acute Respiratory Syndrome)
44
0
0
25
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.1%
4 terminated out of 44 trials
86.2%
-0.3% vs benchmark
18%
8 trials in Phase 3/4
28%
7 of 25 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 25 completed trials
Clinical Trials (44)
Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation
Follow-up of Covid-19 Long Term Sequelae
Renal Biomarkers in AKI and COVID-19
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]
Quercetin In The Treatment Of SARS-COV 2
Characteristics of Patients With COVID-19 in Meta State, Colombia
Expanded Access to Zofin for Patients With COVID-19
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
Glycine Supplement for Severe COVID-19
Sisonke (Together): OPEN LABEL TRIAL COVID-19